FIELD: biology; medicine.
SUBSTANCE: group of inventions relates to biotechnology and medicine. A pharmaceutical combination and a method for non-small-cell lung cancer treatment based on 5-bromo-2,6-di- (1H-pyrazol-1-yl) pyrimidin-4-amine, as well as the use of 5-bromo-2,6-di- (1H-pyrazol-1-yl) pyrimidin-4-amine for cancer treatment. The pharmaceutical combination contains a therapeutically effective amount of 5-bromo-2,6-di (1H-pyrazol-1-yl) pyrimidin-4-amine of formula (I):
, the pharmaceutical combination contains a therapeutically effective amount of 5-bromo-2,6-di (1H-pyrazol-1-yl) pyrimidin-4-amine of formula (I): or a pharmaceutically acceptable salt thereof and one or more immunotherapeutic agents selected from the group, consisting of anti-CTLA4 antibodies, anti-PD-1 antibodies and anti-PD-L1 antibodies.
EFFECT: oral administration of the compound of the formula (I) significantly reduces the tumor mass, in addition, the compound of the formula (I) has shown a synergistic effect with immunotherapeutic agents in stimulating the immune system for cancer treatment.
31 cl, 10 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| DOSING REGIMEN OF A WNT INHIBITOR AND AN ANTI-PD-1 ANTIBODY MOLECULE IN A COMBINATION | 2018 |
|
RU2767533C2 |
| 1-(4-AMINO-5-BROMO-6-(1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)-1H-PYRAZOL-4-OL AND ITS APPLICATIONS FOR CANCER TREATMENT | 2018 |
|
RU2791531C2 |
| MOLECULES OF ANTIBODIES TO CD73 AND THEIR APPLICATION WAYS | 2018 |
|
RU2791192C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO 4Rα (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2808563C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| MOLECULES OF ANTIBODIES TO PD-1 AND THEIR USE | 2016 |
|
RU2788092C2 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
